Friedrich Laengle

810 total citations
26 papers, 407 citations indexed

About

Friedrich Laengle is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Friedrich Laengle has authored 26 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Surgery and 11 papers in Hepatology. Recurrent topics in Friedrich Laengle's work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Colorectal Cancer Treatments and Studies (8 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Friedrich Laengle is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Colorectal Cancer Treatments and Studies (8 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Friedrich Laengle collaborates with scholars based in Austria, United States and Switzerland. Friedrich Laengle's co-authors include Thomas Gruenberger, D. Depisch, Werner Scheithauer, Gabriela Kornek, Fritz Lang, B. Schuell, Harald Puhalla, M. Penz, Sebastian F. Schoppmann and Johannes Zacherl and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Friedrich Laengle

26 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Friedrich Laengle Austria 10 274 214 190 119 60 26 407
André L. Montagnini Brazil 11 284 1.0× 268 1.3× 217 1.1× 85 0.7× 54 0.9× 16 445
Melvin Lau United States 5 159 0.6× 176 0.8× 112 0.6× 82 0.7× 140 2.3× 8 379
Andrea Tufo Italy 10 161 0.6× 181 0.8× 132 0.7× 62 0.5× 27 0.5× 19 310
Dong Do You South Korea 13 381 1.4× 434 2.0× 266 1.4× 41 0.3× 112 1.9× 22 574
Satoshi Hatano Japan 11 213 0.8× 178 0.8× 129 0.7× 39 0.3× 17 0.3× 49 355
Stephanie H. Y. Lau Hong Kong 6 191 0.7× 94 0.4× 162 0.9× 84 0.7× 43 0.7× 10 310
Qinglong Jiang China 11 121 0.4× 173 0.8× 120 0.6× 45 0.4× 38 0.6× 16 247
Katsuyoshi Hatakeyama Japan 10 237 0.9× 152 0.7× 169 0.9× 101 0.8× 82 1.4× 20 360
Keiichiro Inoue Japan 9 238 0.9× 221 1.0× 132 0.7× 145 1.2× 20 0.3× 24 384
Noriyuki Nishino Japan 12 273 1.0× 178 0.8× 115 0.6× 32 0.3× 59 1.0× 32 419

Countries citing papers authored by Friedrich Laengle

Since Specialization
Citations

This map shows the geographic impact of Friedrich Laengle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friedrich Laengle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friedrich Laengle more than expected).

Fields of papers citing papers by Friedrich Laengle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Friedrich Laengle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friedrich Laengle. The network helps show where Friedrich Laengle may publish in the future.

Co-authorship network of co-authors of Friedrich Laengle

This figure shows the co-authorship network connecting the top 25 collaborators of Friedrich Laengle. A scholar is included among the top collaborators of Friedrich Laengle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Friedrich Laengle. Friedrich Laengle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jonas, Jan Philipp, David Pereyra, Jonas Santol, et al.. (2025). Plasma GLP-1 and metabolic dynamics during human liver regeneration and their association with posthepatectomy liver failure. HepatoBiliary Surgery and Nutrition. 14(1). 49–65. 1 indexed citations
2.
Hametner, Simon, Jutta Bergler‐Klein, Irene Kuehrer, et al.. (2025). Incidence and Immunopathology of Myositis in Rectal Cancer Patients Treated With Neoadjuvant Immune Checkpoint Inhibitors and Chemoradiotherapy: Findings From the CHINOREC Trial. MedComm. 6(7). e70275–e70275. 1 indexed citations
3.
Santol, Jonas, Birgit Gruenberger, A. Lenauer, et al.. (2024). Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial. Cancers. 16(5). 857–857. 1 indexed citations
4.
Santol, Jonas, David Pereyra, Johannes Laengle, et al.. (2023). Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration. Scientific Reports. 13(1). 15980–15980. 4 indexed citations
5.
Laengle, Johannes, Irene Kuehrer, Dietmar Pils, et al.. (2021). Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.. Journal of Clinical Oncology. 39(15_suppl). TPS3623–TPS3623. 3 indexed citations
6.
7.
Pereyra, David, Dietmar Tamandl, Judith Stift, et al.. (2019). The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. 26(3). 791–799. 26 indexed citations
8.
Pereyra, David, Eva Braunwarth, Michael Gnant, et al.. (2019). The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection. HepatoBiliary Surgery and Nutrition. 8(2). 111–124. 12 indexed citations
9.
Scheithauer, Werner, Gabriela Kornek, Gerald W. Prager, et al.. (2016). Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.. PubMed. 7(2). 234–8. 14 indexed citations
10.
Gruenberger, Thomas, Friedrich Laengle, J. Thaler, et al.. (2010). Pre- and postoperative chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer: A multicenter, single-arm phase II trial—Results of ASSO LM1.. Journal of Clinical Oncology. 28(15_suppl). e14032–e14032. 1 indexed citations
11.
Vormittag, Laurenz, Andreas Gleiß, Werner Scheithauer, et al.. (2009). Limited Value of CA 19-9 in Predicting Early Treatment Failure in Patients with Advanced Pancreatic Cancer. Oncology. 77(2). 140–146. 8 indexed citations
12.
Silberhumer, Gerd R., Fritz Wrba, Sebastian F. Schoppmann, et al.. (2009). Surgery for Gastrointestinal Stromal Tumors of the Stomach. Journal of Gastrointestinal Surgery. 13(7). 1213–1219. 45 indexed citations
13.
Puhalla, Harald & Friedrich Laengle. (2006). Gallbladder cancer – only surgery is curative. European surgery. Supplement/European surgery. 38(2). 100–106. 2 indexed citations
14.
Tamandl, Dietmar, Birgit Gruenberger, Beata Herberger, et al.. (2006). Selective resection of colorectal liver metastases. European Journal of Surgical Oncology. 33(2). 174–182. 29 indexed citations
15.
Gruenberger, Thomas, B. Schuell, Harald Puhalla, et al.. (2004). Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies. European surgery. Supplement/European surgery. 36(5). 317–321. 8 indexed citations
16.
Kornek, Gabriela, B. Schuell, Friedrich Laengle, et al.. (2004). Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology. 15(3). 478–483. 110 indexed citations
17.
Puhalla, Harald, Daniela Kandioler, Christian Ludwig, et al.. (2004). p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry.. PubMed. 24(2C). 1201–6. 15 indexed citations
18.
Puhalla, Harald, Evelyne Bareck, H. Pokorny, et al.. (2002). Long-term follow-up of surgically treated gallbladder cancer patients. European Journal of Surgical Oncology. 28(8). 857–863. 47 indexed citations
19.
Salat, Andreas, et al.. (1996). Influence of UW solution on in vitro platelet aggregability. Transplant International. 9(s1). S429–S431. 1 indexed citations
20.
Salat, Andreas, et al.. (1996). Influence of UW solution on in vitro platelet aggregability. Transplant International. 9 Suppl 1. 429–431. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by André L. Montagnini Breakdown of academic impact, for papers by Melvin Lau Breakdown of academic impact, for papers by Andrea Tufo Breakdown of academic impact, for papers by Dong Do You Breakdown of academic impact, for papers by Satoshi Hatano Breakdown of academic impact, for papers by Stephanie H. Y. Lau Breakdown of academic impact, for papers by Qinglong Jiang Breakdown of academic impact, for papers by Katsuyoshi Hatakeyama Breakdown of academic impact, for papers by Keiichiro Inoue Breakdown of academic impact, for papers by Noriyuki Nishino
Rankless by CCL
2026